Clinical trial
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT07520565 is registered in ClinicalTrials.gov with Biocells (Beijing) Biotech Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
- Lead sponsor
- Biocells (Beijing) Biotech Co.,Ltd
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 19, 2026
- Completion date
- December 31, 2027
- Enrollment
- 1,112 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
ais